Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. more
Time Frame | TNXP | Sector | S&P500 |
---|---|---|---|
1-Week Return | 177.53% | -3.72% | -0.05% |
1-Month Return | 291.05% | -1.85% | 2.75% |
3-Month Return | 252.61% | -11.4% | 7.4% |
6-Month Return | -53.56% | -4.41% | 10.47% |
1-Year Return | -97.56% | 4.13% | 27.57% |
3-Year Return | -99.98% | 0.3% | 29.56% |
5-Year Return | -99.99% | 36.62% | 89.3% |
10-Year Return | -100% | 106.81% | 206.09% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | 7.77M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 28.83M | 50.51M | 92.31M | 112.09M | 4.74M | [{"date":"2019-12-31","value":25.72,"profit":true},{"date":"2020-12-31","value":45.06,"profit":true},{"date":"2021-12-31","value":82.35,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":4.23,"profit":true}] |
Gross Profit | (28.83M) | (50.51M) | (92.31M) | (112.09M) | 3.03M | [{"date":"2019-12-31","value":-952.36,"profit":false},{"date":"2020-12-31","value":-1668.68,"profit":false},{"date":"2021-12-31","value":-3049.62,"profit":false},{"date":"2022-12-31","value":-3703.04,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | - | - | - | - | 38.97% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 28.83M | 50.51M | 92.31M | 112.09M | 121.41M | [{"date":"2019-12-31","value":23.74,"profit":true},{"date":"2020-12-31","value":41.6,"profit":true},{"date":"2021-12-31","value":76.04,"profit":true},{"date":"2022-12-31","value":92.33,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (28.83M) | (50.51M) | (92.31M) | (112.09M) | (118.38M) | [{"date":"2019-12-31","value":-2882800000,"profit":false},{"date":"2020-12-31","value":-5051100000,"profit":false},{"date":"2021-12-31","value":-9231200000,"profit":false},{"date":"2022-12-31","value":-11209100000,"profit":false},{"date":"2023-12-31","value":-11838000000,"profit":false}] |
Total Non-Operating Income/Expense | 420.00K | 96.00K | 50.00K | 3.75M | 4.49M | [{"date":"2019-12-31","value":9.36,"profit":true},{"date":"2020-12-31","value":2.14,"profit":true},{"date":"2021-12-31","value":1.11,"profit":true},{"date":"2022-12-31","value":83.52,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (28.62M) | (50.46M) | (92.29M) | (110.22M) | (116.66M) | [{"date":"2019-12-31","value":-2861800000,"profit":false},{"date":"2020-12-31","value":-5046300000,"profit":false},{"date":"2021-12-31","value":-9228700000,"profit":false},{"date":"2022-12-31","value":-11021800000,"profit":false},{"date":"2023-12-31","value":-11665800000,"profit":false}] |
Income Taxes | (236.00K) | (75.00K) | (75.00K) | 4.79M | (1.00) | [{"date":"2019-12-31","value":-4.93,"profit":false},{"date":"2020-12-31","value":-1.57,"profit":false},{"date":"2021-12-31","value":-1.57,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (28.38M) | (50.39M) | (92.21M) | (115.00M) | (116.66M) | [{"date":"2019-12-31","value":-2838200000,"profit":false},{"date":"2020-12-31","value":-5038800000,"profit":false},{"date":"2021-12-31","value":-9221200000,"profit":false},{"date":"2022-12-31","value":-11500400000,"profit":false},{"date":"2023-12-31","value":-11665799900,"profit":false}] |
Income From Continuous Operations | (28.62M) | (50.46M) | (92.29M) | (110.22M) | (121.02M) | [{"date":"2019-12-31","value":-2861800000,"profit":false},{"date":"2020-12-31","value":-5046300000,"profit":false},{"date":"2021-12-31","value":-9228700000,"profit":false},{"date":"2022-12-31","value":-11021800000,"profit":false},{"date":"2023-12-31","value":-12101600000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (28.38M) | (50.39M) | (92.21M) | (115.00M) | (116.66M) | [{"date":"2019-12-31","value":-2838200000,"profit":false},{"date":"2020-12-31","value":-5038800000,"profit":false},{"date":"2021-12-31","value":-9221200000,"profit":false},{"date":"2022-12-31","value":-11500400000,"profit":false},{"date":"2023-12-31","value":-11665800000,"profit":false}] |
EPS (Diluted) | (990.40) | (23.04) | (8.32) | (4.07) | (8.62) | [{"date":"2019-12-31","value":-99040,"profit":false},{"date":"2020-12-31","value":-2304,"profit":false},{"date":"2021-12-31","value":-832,"profit":false},{"date":"2022-12-31","value":-407,"profit":false},{"date":"2023-12-31","value":-862,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
TNXP | |
---|---|
Cash Ratio | 1.86 |
Current Ratio | 3.33 |
Quick Ratio | 2.81 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
TNXP | |
---|---|
ROA (LTM) | -51.72% |
ROE (LTM) | -163.24% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
TNXP | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.22 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.78 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
TNXP | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 3.43 |
P/B | 0.51 |
Price/FCF | NM |
EV/R | 1.62 |
EV/Ebitda | 0.94 |
PEG | NM |
Tonix Pharmaceuticals Holding Corp (TNXP) share price today is $0.53
Yes, Indians can buy shares of Tonix Pharmaceuticals Holding Corp (TNXP) on Vested. To buy Tonix Pharmaceuticals Holding Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TNXP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Tonix Pharmaceuticals Holding Corp (TNXP) via the Vested app. You can start investing in Tonix Pharmaceuticals Holding Corp (TNXP) with a minimum investment of $1.
You can invest in shares of Tonix Pharmaceuticals Holding Corp (TNXP) via Vested in three simple steps:
The 52-week high price of Tonix Pharmaceuticals Holding Corp (TNXP) is $22.14. The 52-week low price of Tonix Pharmaceuticals Holding Corp (TNXP) is $0.12.
The price-to-earnings (P/E) ratio of Tonix Pharmaceuticals Holding Corp (TNXP) is
The price-to-book (P/B) ratio of Tonix Pharmaceuticals Holding Corp (TNXP) is 0.51
The dividend yield of Tonix Pharmaceuticals Holding Corp (TNXP) is 0.00%
The market capitalization of Tonix Pharmaceuticals Holding Corp (TNXP) is $42.78M
The stock symbol (or ticker) of Tonix Pharmaceuticals Holding Corp is TNXP